

CORRECTION

Open Access



# Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma

Weipu Mao<sup>1,2,3†</sup>, Keyi Wang<sup>4†</sup>, Bin Xu<sup>1,2\*†</sup>, Hui Zhang<sup>5†</sup>, Si Sun<sup>1</sup>, Qiang Hu<sup>1</sup>, Lei Zhang<sup>1</sup>, Chunhui Liu<sup>1</sup>, Shuqiu Chen<sup>1</sup>, Jianping Wu<sup>1</sup>, Ming Chen<sup>1,2,3\*</sup>, Wei Li<sup>4\*</sup> and Bo Peng<sup>4\*</sup>

## Correction to: *Mol Cancer* 20, 142 (2021).

<https://doi.org/10.1186/s12943-021-01443-2>

Following the publication of the original article [1], the authors found out that the Additional file 1 is outdated. Updated version is contained on this article, see Additional file section.

The original article has been corrected.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12943-021-01459-8>.

Additional file 1.

## Author details

<sup>1</sup>Department of Urology, Affiliated Zhongda Hospital of Southeast University, No. 87 Dingjiaqiao, Hunan Road, Gulou District, Nanjing 210009,

The original article can be found online at <https://doi.org/10.1186/s12943-021-01459-8>.

\*Correspondence: [njxb1982@126.com](mailto:njxb1982@126.com); [mingchenseu@126.com](mailto:mingchenseu@126.com); [liweitongji@163.com](mailto:liweitongji@163.com); [pengbo6908@163.com](mailto:pengbo6908@163.com)

<sup>†</sup>Weipu Mao, Keyi Wang, Bin Xu and Hui Zhang contributed equally to this work.

<sup>1</sup> Department of Urology, Affiliated Zhongda Hospital of Southeast University, No. 87 Dingjiaqiao, Hunan Road, Gulou District, Nanjing 210009, China

<sup>3</sup> Department of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, China

<sup>4</sup> Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai 200072, China

Full list of author information is available at the end of the article

China. <sup>2</sup>Surgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing 210009, China. <sup>3</sup>Department of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, China. <sup>4</sup>Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai 200072, China. <sup>5</sup>Department of Anesthesiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.

Published online: 01 December 2021

## Reference

1. Mao W, Wang K, Xu B, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. *Mol Cancer*. 2021;**20**:142. <https://doi.org/10.1186/s12943-021-01443-2>.



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.